QNCX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quince Therapeutics Inc (QNCX) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's recent Phase 3 trial failure has resulted in significant downgrades from analysts, with some assigning a zero-value target. The financials are weak, with no revenue and a significant drop in net income. Additionally, there are no positive catalysts or trading signals to suggest a recovery. Given the lack of growth prospects and negative sentiment, selling or avoiding this stock is recommended.
The MACD is slightly positive at 0.252, indicating mild bullish momentum, but it is contracting. RSI is neutral at 54.278, showing no clear trend. Moving averages are converging, suggesting indecision. The stock is trading near its support level of 0.877, with resistance levels far above at 3.145 and 3.845. Overall, the technical indicators do not provide a strong buy signal.
NULL identified. No recent news or events suggest any positive catalysts for the stock.
The company's Phase 3 NEAT clinical trial failed to achieve statistical significance, leading to the discontinuation of its core asset. Analysts have downgraded the stock significantly, with one assigning a price target of 0c. Financials are weak, with no revenue and a 100% drop in net income YoY. There is no insider or hedge fund activity indicating confidence in the stock.
In 2025/Q4, the company reported no revenue growth (0% YoY) and a 100% drop in net income. EPS improved to -1.68, but this is still negative. Gross margin remains at 0%. Overall, the financial performance is poor, with no signs of growth or profitability.
Analysts have downgraded the stock heavily following the Phase 3 trial failure. D. Boral Capital downgraded it to Hold, Maxim downgraded it to Hold, Lucid Capital downgraded it to Sell with a 0c price target, and Citizens downgraded it to Market Perform. The consensus is overwhelmingly negative, with no positive outlook for the stock.
